222 related articles for article (PubMed ID: 27634873)
21. Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Apoptosis; 2016 Dec; 21(12):1422-1437. PubMed ID: 27734217
[TBL] [Abstract][Full Text] [Related]
22. Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.
Han SS; Han S; Kamberos NL
Biochem Biophys Res Commun; 2014 Sep; 452(3):669-75. PubMed ID: 25193702
[TBL] [Abstract][Full Text] [Related]
23. Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.
Lee JC; Ahn KS; Jeong SJ; Jung JH; Kwon TR; Rhee YH; Kim SH; Kim SY; Yoon HJ; Zhu S; Chen CY; Kim SH
J Cell Biochem; 2011 Jun; 112(6):1552-62. PubMed ID: 21344490
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
26. A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib.
Chen G; Hu K; Sun H; Zhou J; Song D; Xu Z; Gao L; Lu Y; Cheng Y; Feng Q; Zhang H; Wang Y; Hu L; Lu K; Wu X; Li B; Zhu W; Shi J
Cancer Lett; 2020 May; 478():45-55. PubMed ID: 32160976
[TBL] [Abstract][Full Text] [Related]
27. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
[TBL] [Abstract][Full Text] [Related]
28. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
29. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
30. Patrinia scabiosaefolia extract suppresses proliferation and promotes apoptosis by inhibiting the STAT3 pathway in human multiple myeloma cells.
Peng J; Chen Y; Lin J; Zhuang Q; Xu W; Hong Z; Sferra TJ
Mol Med Rep; 2011; 4(2):313-8. PubMed ID: 21468570
[TBL] [Abstract][Full Text] [Related]
31. Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.
Dimberg LY; Dimberg A; Ivarsson K; Fryknäs M; Rickardson L; Tobin G; Ekman S; Larsson R; Gullberg U; Nilsson K; Öberg F; Wiklund HJ
BMC Cancer; 2012 Jul; 12():318. PubMed ID: 22838736
[TBL] [Abstract][Full Text] [Related]
32. Induction of cell cycle arrest and apoptosis by CPUC002 through stabilization of p53 and suppression of STAT3 signaling pathway in multiple myeloma.
Zhao Y; Bai D; Du J; Ren H; Zhang Z; Jiang C; Lu N
Cell Biol Toxicol; 2021 Feb; 37(1):97-111. PubMed ID: 33126266
[TBL] [Abstract][Full Text] [Related]
33. A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.
Lin L; Benson DM; DeAngelis S; Bakan CE; Li PK; Li C; Lin J
Int J Cancer; 2012 Mar; 130(6):1459-69. PubMed ID: 21520044
[TBL] [Abstract][Full Text] [Related]
34. BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway.
Wu XY; Tian F; Su MH; Wu M; Huang Y; Hu LH; Jin L; Zhu XJ
Int Immunopharmacol; 2018 Nov; 64():24-32. PubMed ID: 30145467
[TBL] [Abstract][Full Text] [Related]
35. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
Guan M; Zhu L; Somlo G; Hughes A; Zhou B; Yen Y
Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
[TBL] [Abstract][Full Text] [Related]
37. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells.
Park S; Lee HJ; Jeong SJ; Song HS; Kim M; Lee HJ; Lee EO; Kim DH; Ahn KS; Kim SH
Food Chem Toxicol; 2011 Jun; 49(6):1367-72. PubMed ID: 21420464
[TBL] [Abstract][Full Text] [Related]
39. Piperlongumine Induces Reactive Oxygen Species (ROS)-Dependent Downregulation of Specificity Protein Transcription Factors.
Karki K; Hedrick E; Kasiappan R; Jin UH; Safe S
Cancer Prev Res (Phila); 2017 Aug; 10(8):467-477. PubMed ID: 28673967
[TBL] [Abstract][Full Text] [Related]
40. Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells.
Starheim KK; Holien T; Misund K; Johansson I; Baranowska KA; Sponaas AM; Hella H; Buene G; Waage A; Sundan A; Bjørkøy G
Blood Cancer J; 2016 Jul; 6(7):e446. PubMed ID: 27421095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]